amda
$DCGO DocGo remains on track to exit fiscal year 2026 with positive adjusted EBITDA in its core business. Needham stated the risk/reward profile remains attractive for DocGo shares at current levels. InvestingPro analysis suggests the stock is undervalued based on its Fair Value assessment, with the company appearing on the platform’s most undervalued stocks screening.
The firm maintained its $3.00 price target on the stock.
1
1
